{"id":"butazolamide","rwe":[{"pmid":"35127639","year":"2021","title":"1,3,4-Thiadiazole Scaffold: As Anti-Epileptic Agents.","finding":"","journal":"Frontiers in chemistry","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Active","category":"status"}],"phase":"unknown","safety":{},"trials":[],"aliases":[],"patents":[],"pricing":[],"_fixedAt":"2026-03-30T16:38:59.854365","allNames":["butazolamide"],"offLabel":[],"synonyms":["butazolamide"],"timeline":[],"ecosystem":[],"mechanism":{"modality":"Small Molecule","explanation":"Think of it like a leaky faucet - carbonic anhydrase helps regulate the amount of acid in the body by controlling the flow of fluids. Butazolamide blocks this enzyme, which can help reduce the amount of acid in the body and alleviate symptoms of certain conditions.","oneSentence":"Butazolamide works by inhibiting the enzyme carbonic anhydrase, which plays a crucial role in maintaining acid-base balance in the body.","technicalDetail":"Butazolamide acts as a reversible inhibitor of carbonic anhydrase, specifically targeting the enzyme's active site and preventing the conversion of carbon dioxide to bicarbonate and protons."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/3693","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=butazolamide","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T09:06:22.786612","biosimilars":[],"competitors":[],"genericName":"butazolamide","indications":{"approved":[],"offLabel":[],"pipeline":[]},"_fixedFields":["pubmed(1)"],"drugCategory":"active","labelChanges":[],"relatedDrugs":[],"trialDetails":[],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"0S326CI0WT","PDB_CHEM_ID":"VFJ","PUBCHEM_CID":"519309"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[],"publicationCount":1,"therapeuticAreas":["Other"],"biosimilarFilings":[],"recentPublications":[{"date":"2021","pmid":"35127639","title":"1,3,4-Thiadiazole Scaffold: As Anti-Epileptic Agents.","journal":"Frontiers in chemistry"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"active","brandName":"butazolamide","companyName":"","companyId":"unknown","modality":"Small Molecule","firstApprovalDate":"","aiSummary":"Butazolamide is a small molecule drug with unknown target and drug class. It is not FDA approved for any indications. The commercial status of butazolamide is unclear, and it may be off-patent. Butazolamide's pharmacokinetic properties, such as half-life and bioavailability, are also unknown. Further research is needed to understand its mechanism of action and potential therapeutic applications.","enrichmentLevel":3,"visitCount":0,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":false,"score":1}}